Cardiac fibroblast cell surface receptor

Cardiac fibroblast cell surface receptors are a diverse group of membrane-bound proteins found on cardiac fibroblasts, the most abundant non-myocyte cells in the heart responsible for producing extracellular matrix (ECM), regulating myocardial structure, and driving both physiological repair and pathological remodeling[2][3][1]. Prominent receptor types include platelet-derived growth factor receptor alpha (PDGFRα), discoidin domain receptor 2 (DDR2), CD90/Thy1, and fibroblast-specific protein 1 (FSP1), among others[2][3]. These receptors mediate critical signaling pathways in response to growth factors, cytokines, and matrix signals—governing fibroblast proliferation, ECM deposition, and fibrotic transformation. Aberrant activation or signaling through these receptors is central to the progression of cardiac fibrosis, contributing to stiffening of heart tissue, impaired function, and arrhythmias in various forms of cardiovascular disease[1][4]. Due to their key roles in disease progression and their cell-surface accessibility, these receptors are under investigation as therapeutic targets and as biomarkers for cardiac pathology[3][2].\n\nImportant notes regarding naming and specificity:\n- The query refers broadly to a class (not a single molecule). This is *not* the canonical name for a specific target, but rather denotes a collection of individual receptors.\n- Thus, **is_incorrect: true**, because the target is a group/category and not a unique, canonical molecular entity as typically required for target databases.\n\nFor structured data, entries should specify individual receptors whenever possible, as clinical/drug relevance is determined at the level of distinct proteins (e.g., \"PDGFRα\", \"DDR2\"), not general cell categories.

Other names

Cardiac fibroblast markerCardiac fibroblast receptorCardiac fibroblast surface antigen

Inhibition of receptor-mediated fibrogenic signaling\nModulation of growth factor signaling (e.g., PDGFRα or TGFβ blocking)\nPrevention of fibroblast-to-myofibroblast transition